-
KEYTRUDA® (pembrolizumab) and KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph), Plus Paclitaxel ± Bevacizumab, Approved for Certain Adults with PD-L1+ (CPS ≥1) Platinum-Resistant Ovarian Carcinoma as Second or Third Line Treatment
11 Feb 2026 17:30 GMT
… metastatic non–small cell lung cancer (NSCLC), serious adverse … and paclitaxel followed by doxorubicin or epirubicin and cyclophosphamide) … .
Non-Small Cell Lung Cancer
KEYTRUDA and KEYTRUDA QLEX … nonsquamous non–small cell lung cancer (NSCLC), with no …
-
Filamentous Phage for Therapeutic Applications in Non-Small Cell Lung Cancer and Brain Metastases: Recent Prospect
19 Jan 2026 18:47 GMT
… phages specifically binding to lung cancer tumors.
Principles of … chemotherapeutics (eg, paclitaxel, doxorubicin) or toxins to … successfully applied to target lung cancer cells, especially brain … in lung cancer patients or using transplanted lung cancer animal …
-
Phytochemical and Anti-Ischemic Stroke Properties from the Vitex L. Genus
10 Feb 2026 22:10 GMT
… subclasses as cardioprotective agents against doxorubicin-induced cardiotoxicity: a comprehensive review … and mitochondria permeability transition in lung cancer cells. Biomedicines. 2024;12(3 …
-
Racura secures $3.2M for lung cancer trial - ICYMI
12 Dec 2025 10:55 GMT
… osimertinib, targeting EGFR-mutant lung cancer.
The company told investors … investigating RC220 in combination with doxorubicin — will be published throughout … drive a portion of lung cancer, and drugs like … of RC220 combined with doxorubicin, so we expect data …
-
Regionals at the Rotunda: Alexis Evans and C.J. Johnston
09 Feb 2026 22:29 GMT
… varies greatly. Most lung cancer patients continue to receive … paclitaxel, cisplatin, and doxorubicin. Using laboratory cellular models … involves engineering human lung cancer cells to explore … involves engineering human lung cancer cells to explore …
-
Race Oncology launches new clinical programs in AML and lung cancer
17 Nov 2025 00:12 GMT
… EGFR-mutated non-small cell lung cancer (NSCLC) as the … a critical challenge.
New lung cancer program advances
Race has moved … on RC220 in combination with doxorubicin, aimed at providing both … full clinical trial program in lung cancer in under nine months.” …
-
The Intricate Web of MicroRNAs in Modulating EGFR-TKI Resistance in Non-Small Cell Lung Cancer: A Comprehensive Review
11 Nov 2025 07:13 GMT
… osimertinib resistance in lung cancer by inhibiting the CD44 … sensitizing EGFR mutations in lung cancer activate anti-apoptotic pathways … non-small cell lung cancer. Transl Lung Cancer Res. 2022;11 … microRNA-21 inhibitor and doxorubicin. Colloids Surf B …
-
Prospects and Challenges of Chitosan-Based Drug Carriers for Anticancer Agents’ Delivery Against Lung Cancer: A Review
24 Oct 2025 14:10 GMT
… lung cancer into non-small cell lung cancer (NSCLC) and small cell lung cancer … of lung cancer.
Current treatment modalities for lung cancer include … CPT-NPs inhibited lung tumor growth by … doxorubicin to promote necroptosis for mitigating lung cancer cells …
-
Doxorubicin Market Size Worth $1.86 Billion by 2029 - Exclusive Report by The Business Research Company
24 Nov 2025 09:30 GMT
… based in India, introduced Doxorubicin Hydrochloride Liposome Injection. This … Cancer, Sarcoma, Ovarian Cancer, Lung Cancer, Leukemia, Multiple Myeloma, Other … Dilution, Liposomal Doxorubicin Injections
View the full doxorubicin market report: …
-
Application of Pharmaceutical Nanotechnologies for Chinese Herbal Medicines in the Treatment of Pulmonary Diseases and Lung Cancer
05 Sep 2025 03:30 GMT
… inducing apoptosis in doxorubicin-resistant A549 lung cancer cells (A549DR). … pulmonary diseases and lung cancer treatment, including … superior cytotoxicity toward lung cancer cells, highlighting … anticancer activity against lung cancer. In conclusion, …
About
© 1995-2026